We are live on
!
Find out more
VVM
Versant Venture Management Portfolio holdings
AUM
$141M
1-Year Est. Return
190.82%
This Fund
S&P 500
This Quarter
Est. Return
+58.68%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$105M
AUM Growth
–
Cap. Flow
+$85.5M
Cap. Flow
% of AUM
81.8%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$42.8M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$18.8M |
| 3 |
AKAO
Achaogen Inc
AKAO
|
+$13M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
+$8.43M |
| 5 |
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
|
+$2.46M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.68% |
Similar funds
POIA
MAM
TM
IA
KCM
RB
YEPX
CFGW
Versant Venture Management's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for Versant Venture Management, which disclosed 5 positions worth $105M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Clovis Oncology, Inc.: 814,833 shares worth $45.6M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets.
- Versant Venture Management's largest Q4 2014 buy was Clovis Oncology, Inc.: 814,833 shares worth $45.6M.
- Versant Venture Management's ten largest holdings make up 100% of its $105M portfolio in Q4 2014.
- Versant Venture Management disclosed 5 positions in Q4 2014, its first 13F filing on record.
Based on Versant Venture Management's 13F filing for Q4 2014, filed 2 Apr 2015.